In the early 1990s, human epidermal growth factor receptor 2 (HER2) transitioned from a pre-clinical biomarker to a pivotal therapeutic target in HER2-positive breast cancer (HER2+ BC). This evidence concerns the gene ERBB2 and breast cancer.